Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS
NCT06612944Phase 2Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in myelodysplastic syndrome (MDS), sponsored by Shanghai General Hospital. Started Nov 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06612944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612944.